Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy Study in Severe Haemophilia A Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02576795
Recruitment Status : Active, not recruiting
First Posted : October 15, 2015
Last Update Posted : April 17, 2019
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Brief Summary:
This study is being conducted by Biomarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy vector in participants with severe Haemophilia A.

Condition or disease Intervention/treatment Phase
Severe Haemophilia A Genetic: BMN 270 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A
Study Start Date : August 2015
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BMN 270
BMN 270 is administered as a single IV Infusion.
Genetic: BMN 270



Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for 5 years following valoctocogene roxaparvovec infusion. [ Time Frame: 61 Months ]
  2. To determine the dose of AAV5-hFVIII-SQ required to achieve expression of FVIII at or above 5% of normal activity (>5 IU/dL) at 16 weeks after infusion. [ Time Frame: 61 Months ]
    The kinetics, duration and magnitude of AAV-mediated FVIII activity in individuals with haemophilia A will be determined and correlated to an appropriate BMN 270 dose.


Secondary Outcome Measures :
  1. To describe the immune response to the FVIII transgene product and AAV capsid proteins following systemic administration of AAV5-hFVIII-SQ [ Time Frame: 61 Months ]
  2. Frequency of FVIII replacement therapy during the study [ Time Frame: 61 Months ]
  3. Number of bleeding episodes requiring treatment during the study [ Time Frame: 61 Months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males that are 18 years or older with established severe Haemophilia A as evidenced by their medical history. Patients will be considered as severe if their base FVIII level is 1 IU/dL or less
  2. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs)
  3. Greater or equal to 12 bleeding episodes only if on on-demand therapy over the previous 12 months. Does not apply to patients on prophylaxis
  4. Able to sign informed consent and comply with requirements of the trial
  5. No history of inhibitor, and results from a modified Nijmegen Bethesda assay of less than 0.6 Bethesda Units (BU) 2 consecutive occasions at least one week apart within the past 12 months
  6. Sexually active patients must be willing to use an acceptable method of contraception such as double barrier, including hormonal contraception for at least 6 months post-treatment. After 6 months, subjects may stop contraception use only if they have had 3 consecutive negative semen samples.

Exclusion Criteria:

  1. Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies
  2. Any evidence of active infection or any immunosuppressive disorder.
  3. HIV positive
  4. Significant liver dysfunction as defined by abnormal elevation of:

    • ALT (alanine transaminase) to 3 times the upper limit of normal;
    • Bilirubin above 3 times the upper limit of normal;
    • Alkaline phosphatase above 3 times the upper limit of normal; or
    • INR (international normalized ratio) ≥ 1.4.
  5. Potential participants who have had a liver biopsy in the past 3 years are excluded if they had significant fibrosis of 3 or 6. as rated on a scale of 0-4
  6. Evidence of any bleeding disorder not related to Haemophilia A
  7. Platelet count of < 100 x 10^9/L
  8. Creatinine ≥ 1.5 mg/dL
  9. Liver cirrhosis of any etiology as assessed by liver ultrasound
  10. Hepatitis B if surface antigen is positive
  11. Hepatitis C if RNA is positive
  12. Treatment with any IP within 30 days prior to the end of the screening period
  13. Any disease or condition at the physician's discretion that would prevent the patient from fully complying with the requirements of the study including possible corticosteroid treatment outlined in the protocol. The physician may exclude patients unwilling or unable to agree on not using alcohol for the 16-week period following the viral infusion.
  14. Prior treatment with any gene transfer agent
  15. Major surgery planned in the 16-week period following the viral infusion
  16. Use of systemic immunosuppressive agents or live vaccines within 30 days before the viral infusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02576795


Locations
Layout table for location information
United Kingdom
Hampshire Hospitals NHS Foundation Trust
Basingstoke, United Kingdom, RG24 9NA
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom, B15 2TH
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom, BS1 3NU
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom, CB2 0QQ
Greater Glasgow Health Board
Glasgow, United Kingdom, G12 OXH
Barts Health NHS Trust
London, United Kingdom, E1 1BB
Guy's & St. Thomas' NHS Foundation Trust
London, United Kingdom, SE1 7EH
Imperial College Healthcare NHS Trust
London, United Kingdom, W2 1NY
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Layout table for investigator information
Study Director: Medical Director, MD BioMarin Pharmaceutical

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT02576795     History of Changes
Other Study ID Numbers: BMN270-201
2014-003880-38 ( EudraCT Number )
First Posted: October 15, 2015    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by BioMarin Pharmaceutical:
Haemophilia A
Gene Therapy
Clotting Disorders
Blood Disorder
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants
AAV5 vector
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants